ArticleScientific reports2021
Osteopontin levels are associated with late-time lower regional brain volumes in multiple sclerosis.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 16 citations in OpenAlex.
- Evaluation of potential serum biomarkers for individuals at risk of multiple sclerosis.bioRxiv : the preprint server for biology · 2026Article
- The MMP-9/TIMP-1 Ratio and Concentrations of Osteopontin Are Elevated in Cerebrospinal Fluid of People With Multiple Sclerosis and Decrease After Autologous Hematopoietic Stem Cell Transplantation.Annals of clinical and translational neurology · 2026Article
- Tissue repair in the central nervous system: the epigenetic programming of regulatory T cells.Frontiers in immunology · 2026Review
- Comparative analysis reveals distinct metal and inflammatory cytokine profiles in the cerebrospinal fluid of children with neurological disorders.Frontiers in toxicology · 2026Article
- Elevated osteopontin reflects systemic inflammation in experimental autoimmune encephalomyelitis.Anatomy & cell biology · 2025Article
- The Association of Axonal Damage Biomarkers and Osteopontin at Diagnosis Could Be Useful in Newly Diagnosed MS Patients.Neurology international · 2025Article
- Fluid Biomarkers in Demyelinating Spectrum Disorders: Past, Present, and Prospects.International journal of molecular sciences · 2025Review
- Association of Levels of CSF Osteopontin With Cortical Atrophy and Disability in Early Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Osteopontin predicts late-time salience network-related functional connectivity in multiple sclerosis.PloS one · 2024Article
- New Enhancing MRI Lesions Associate with IL-17, Neutrophil Degranulation and Integrin Microparticles: Multi-Omics Combined with Frequent MRI in Multiple Sclerosis.Biomedicines · 2023Article
- Emerging imaging and liquid biomarkers in multiple sclerosis.European journal of immunology · 2023Review
- Circulating microRNAs correlate with structural and functional MRI parameters in patients with multiple sclerosis.Frontiers in molecular neuroscience · 2023Article
- Proteomics and relationship with axonal pathology in multiple sclerosis: 5-year diffusion tensor imaging study.Brain communications · 2023Article
- Biomarkers in autoimmune diseases of the central nervous system.Frontiers in immunology · 2023Review
- Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteopontin (OPN) is a proinflammatory marker produced by systemic immune and central nervous system (CNS) resident cells. We examined, if the level of OPN in the cerebrospinal fluid (CSF) and blood is associated with late-time regional brain volumes and white matter (WM) lesion load in MS. Concentrations of OPN in blood and CSF were related to MRI findings 10.1 ± 2.0 years later in 46 patients with MS. OPN concentration was measured by ELISA, while regional brain volumes and lesion load was assessed by magnetic resonance imaging (MRI) using 3D MPRAGE sequence and automated MR volumetry. OPN measured in the CSF was associated with several regional brain volumes and WM lesion load measured 10.1 ± 2.0 years later. CSF OPN concentration correlated with long-term enlargement of lateral- and inferior lateral ventricles and the elevation of gross CSF volume, in conjunction with the reduction of several cortical/subcortical gray matter and WM volumes. Serum OPN showed no long-term association with regional brain volumes. OPN measured from the CSF but not from the serum was associated with lower regional brain volumes measured a decade later, indicating the primary role of inflammation within the CNS in developing long-term brain related alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.